Cytoki Pharma ApS: Financial statements 2022
CVR: 40594132
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Cytoki Pharma ApS (CVR 40594132) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -98,763,646 and a net result of DKK -98,393,590 compared with DKK -29,753,257 the year before. Equity in the 2022 report amounted to DKK 51,217,006. The solvency ratio was 74.4%. The company had 4 employees in the financial year.
- Gross Profit
- DKK -98,763,646
- Profit/Loss
- DKK -98,393,590
- Equity
- DKK 51,217,006
- Total Assets
- DKK 68,865,246
- Employees
- 4
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -98.8 mio. | -98.4 mio. | 51.2 mio. | 4 |
| 2021 | - | -32 mio. | -29.8 mio. | 106.8 mio. | 3 |
| 2020 | - | -6 mio. | -6.8 mio. | -9.8 mio. | 1 |
Official annual report
Keep an eye on Cytoki Pharma ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
As of December 19, 2022, 15-Bio ApS is registered as an owner of Cytoki Pharma ApS with an ownership share of 10%.
Cytoki Pharma ApS has published its annual report for 2021. Gross profit came to DKK -31,975,161, and the net result was DKK -29,753,257.
About Cytoki Pharma ApS
Cytoki Pharma ApS is a Danish company of the type Anpartsselskab based in Søborg, founded in 2019. The company is in liquidation. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named CytoKi Pharma ApS. The management consists of Anders Hagstrøm. The company's owners include LUNDBECKFOND INVEST A/S, 15-Bio ApS and YSIOS Biofund III, F.C.R.E. The company has 3 employees (2026). In 2025, the company reported a gross profit of DKK -42,198,706 and a net result of DKK -43,800,007 compared with DKK -39,261,697 the year before. Equity in the 2025 report amounted to DKK 13,473,548.